Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02277457
Recruitment Status : Withdrawn
First Posted : October 29, 2014
Last Update Posted : June 24, 2016
Sponsor:
Collaborator:
Augusta University
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Brief Summary:

Hypotheses:

Short-term - Targeted therapy with erlotinib or crizotinib plus PART (Personalized Adaptive Radiation Therapy) will be safe and will yield favorable outcomes in patients with stage III, EGFR (Epidermal Growth Factor Receptor) + or ALK (Anaplastic Lymphoma Kinase) + NSCLC (Non-Small Cell Lung Cancer).

Long-term - In patients with stage III NSCLC harboring driver mutations, treatment with relevant targeted agents plus PART will improve both local-regional and systemic tumor control resulting in improved survival relative to standard chemoradiotherapy.


Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Radiation: PET-Adaptive RT Drug: Erlotinib Drug: Crizotinib Early Phase 1

Detailed Description:

The proposed trial is a pilot study that will accrue 30 patients with inoperable stage IIIA/B NSCLC harboring either an EGFR mutation (n=20) or an ALK rearrangement (n=10). Patients with EGFR+ tumors will be treated with erlotinib 150 mg orally QD; patients with ALK+ tumors will be treated with crizotinib 250 mg orally BID. Treatment consists of six weeks of concurrent PART plus erlotinib or crizotinib, followed by erlotinib or crizotinib for a total of 1 year. All patients will be treated with response-driven PART with dose intensified to the active (FDG-avid) region based on a mid-treatment FDG-PET/CT scan while maintaining dose limits for organs-at-risk. The primary endpoints will be PFS and OS. Primary analyses will be performed separately for ALK+ and EGFR+ patients. The secondary endpoint of treatment-related toxicity will focus on pneumonitis and esophagitis with a strict stopping rule in place.

Current standard therapy affords suboptimal outcomes for patients with locally advanced NSCLC due to both locoregional and distant recurrences. Since targeted therapy is more effective than chemotherapy in patients with relevant driver mutations, the best way to significantly improve outcomes in this subgroup of patients is to optimize systemic therapy with targeted agents while improving local control with PET-adapted, high-dose RT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Study Start Date : September 2015
Estimated Primary Completion Date : June 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Crizotinib

Arm Intervention/treatment
Experimental: EGFR Mutation
Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Erlotinib followed by 1 year total of Erlotinib Treatment.
Radiation: PET-Adaptive RT
All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.

Drug: Erlotinib
150 mg once daily

Experimental: ALK Rearrangement
Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Crizotinib followed by 1 year total ofCrizotinib Treatment.
Radiation: PET-Adaptive RT
All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.

Drug: Crizotinib
250 mg twice daily




Primary Outcome Measures :
  1. Time to Progression From the Initiation of Study Treatment For ALK + and EGFR + Patients [ Time Frame: 5 Years ]
  2. Time to Death From Initiation of Study Treatment For ALK + and EGFR + Patients [ Time Frame: 5 Years ]

Secondary Outcome Measures :
  1. The Number of Patients Experiencing Pneumonitis and Esophagitis [ Time Frame: 5 Years ]
  2. The Number of Patients Experiencing Grade 3 or Higher Toxicities [ Time Frame: 5 Years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with FDG-avid (radioactive glucose) and pathologically proven stage IIA-IIB or IIIA-IIIB non-small cell lung cancer (according to AJCC [American Joint Committee on Cancer] staging, 7th edition).
  • Patients with tumors that harbor either EGFR sensitizing mutations or ALK rearrangement.
  • Patients must be considered unresectable or medically inoperable; patients who decline surgery are also eligible.
  • Patients must be 18 years of age or older.
  • Patients with ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.
  • Patients must have adequate organ function.
  • Patients must be able to take oral medications.
  • Women with reproductive capability must be willing to use effective contraception.
  • Patients must be informed of the investigational nature of this study and sign written informed consent in accordance with institutional and federal guidelines.
  • Patients must be willing to comply with study procedures.

Exclusion Criteria:

  • Patients with tumors that have a component of small cell carcinoma.
  • Patients wtih stage I, II, or IV disease, including malignant pleural or pericardial effusion.
  • Prior radiotherapy to the thorax such that composite radiation would significantly over-dose critical structures, either per estimation of the treating radiation oncologist or defined by failure to meet normal tissue tolerance constraints.
  • Patients who cannot tolerate thoracic radiotherapy or targeted therapy.
  • Patients wtih a prior diagnosis of interstitial lung disease or pulmonary fibrosis.
  • Patients who cannot take oral medication, require intravenous alimentation, had prior surgical procedures affecting gastrointestinal absorption, or have active peptic ulcer disease.
  • Hypersensitivity to erlotinib, crizotinib, or to any of the excipients.
  • Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects.
  • Prisoners are excluded from this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02277457


Locations
Layout table for location information
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48187
Sponsors and Collaborators
University of Michigan Rogel Cancer Center
Augusta University
Investigators
Layout table for investigator information
Principal Investigator: Gregory Kalemkerian, M.D. University of Michigan Rogel Cancer Center
Layout table for additonal information
Responsible Party: University of Michigan Rogel Cancer Center
ClinicalTrials.gov Identifier: NCT02277457    
Other Study ID Numbers: UMCC 2014.117
HUM00094166 ( Other Identifier: University of Michigan )
First Posted: October 29, 2014    Key Record Dates
Last Update Posted: June 24, 2016
Last Verified: June 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Crizotinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action